Table 2.
Cox regression analysis of golimumab discontinuation
| Baseline characteristics | Adjusted HR* | 95% CI | p value |
|---|---|---|---|
| Age | 0.999 | 0.980–1.019 | 0.927 |
| Sex | |||
| Male | Ref | ||
| Female | 0.810 | 0.622–1.054 | 0.117 |
| eGFR | |||
| High | Ref | ||
| Moderate | 0.917 | 0.683–1.231 | 0.562 |
| Low | 0.859 | 0.600–1.228 | 0.405 |
| C-reactive protein (mg/dL) | 1.049 | 1.012–1.087 | 0.009 |
| Hypertension | |||
| No | Ref | ||
| Yes | 1.013 | 0.778–1.320 | 0.924 |
| Diabetes mellitus | |||
| No | Ref | ||
| Yes | 1.101 | 0.868–1.396 | 0.430 |
| Hyperlipidemia | |||
| No | Ref | ||
| Yes | 1.075 | 0.826–1.399 | 0.588 |
| Chronic lung disease | |||
| No | Ref | ||
| Yes | 1.007 | 0.766–1.323 | 0.963 |
| Maintenance golimumab dosage | |||
| 50 mg per 4 weeks | Ref | ||
| 100 mg per 4 weeks | 0.976 | 0.733–1.301 | 0.871 |
| Concomitant csDMARD | |||
| GLM alone | Ref | ||
| Concomitant MTX | 0.661 | 0.481–0.909 | 0.011 |
| Concomitant csDMARD except MTX | 0.950 | 0.667–1.354 | 0.777 |
| Concomitant NSAIDs | |||
| No | Ref | ||
| Yes | 1.086 | 0.845–1.395 | 0.520 |
| Prior use of biologics | |||
| Yes | Ref | ||
| No | 1.146 | 0.895–1.468 | 0.281 |
| Concomitant corticosteroid | |||
| No | Ref | ||
| Yes | 0.992 | 0.788–1.248 | 0.942 |
eGFR estimated glomerular filtration rate, GLM golimumab, MTX methotrexate, NSAID non-steroidal anti-inflammatory drugs, csDMARD conventional synthetic disease-modifying anti rheumatic drug, HR hazard ratio, CI confidence interval